FIELD: pharmaceutics.
SUBSTANCE: invention relates to compounds of formula I or pharmaceutically acceptable salts possessing antibacterial action,
,
wherein R1a represents H or carboxy and R1b represents H, or R1a and R1b represent together or group *-C(O)-NH-S-# or group *-C(OH)=N-S-# in which "*" is connection point of R1a and "#" is connection point of R1b; R2 represents H, (C1-C3)alkyl, hydroxy-(C1-C3)alkyl, benzyl or (C3-C5)cycloalkyl; R3 represents H or halogen; U is N or CR4; wherein R4 represents H or (C1-C3)alkoxy; A represents CH, B represents NH and m is 1 or 2 and n is 1 or 2; or A is N, B is absent, m is 2 and n is 2; Y represents CH or N; and Q represents O or S. Invention also relates to pharmaceutical composition.
EFFECT: novel compounds are obtained, which can be used for preventing or treating bacterial infections.
15 cl, 25 ex
Title | Year | Author | Number |
---|---|---|---|
TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS | 2009 |
|
RU2530884C2 |
OXAZOLIDINE ANTIBIOTICS | 2009 |
|
RU2516701C2 |
5-AMINOCYCLYLMETHYLOXAZOLIDIN-2-ONE DERIVATIVES | 2008 |
|
RU2492169C2 |
AZETIDINE DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF HAVING ANTIMICROBIAL ACTIVITY | 1991 |
|
RU2044735C1 |
NOVEL CONDENSED PYRIDINE DERIVATIVES USED AS C-MET TYROSINE KINASE INHIBITORS | 2013 |
|
RU2619130C2 |
DERIVATIVES OF 2-IMINOPYRROLIDINE | 2002 |
|
RU2270192C2 |
BRUTON'S TYROSINE KINASE INHIBITORS | 2010 |
|
RU2542585C2 |
AMINOMETHYL QUINOLONES USEFUL IFOR TREATMENT OF JNK-MEDIATED DISORDER | 2012 |
|
RU2629111C2 |
OXAZOLIDINONE DERIVATIVES | 2009 |
|
RU2501799C2 |
SPIRO CONDENSED PYRROLIDINE DERIVATIVES AS INHIBITORS OF DEUBIQUITINATING ENZYMES (DUB) | 2017 |
|
RU2730552C2 |
Authors
Dates
2017-04-18—Published
2012-11-07—Filed